Filing summary
Entity mismatch: The supplied filing is ReShape Lifesciences Inc.’s Form 10-Q, not a filing for Vyome Holdings, Inc. It covers the quarter ended March 31, 2022. Financial amounts below are in thousands of dollars unless noted.
Business context and results
ReShape sells obesity-treatment products and services, with nearly all reported revenue and gross profit coming from the LAP-BAND system. ReShape care had minimal revenue; the ReShape Vest and Diabetes Bloc-Stim Neuromodulation were still in development, and the acquired Obalon product line generated no revenue in the quarter.
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $2,440 | $3,221 |
| Gross profit / margin | $1,218 / 50.0% | $2,284 / 70.9% |
| Operating expenses | $9,618 | $4,541 |
| Operating loss | $(8,400) | $(2,257) |
| Net loss | $(8,215) | $(4,874) |
| Net loss per share, diluted | $(0.44) | $(1.24) |
| Non-GAAP loss | $(7,076) | $(1,771) |
| Cash used in operations | $(7,378) | $(1,961) |
Cash and cash equivalents were $15,410 at March 31, 2022, down from $22,765 at December 31, 2021; restricted cash was $50. Net working capital was approximately $15.5 million. The company reported no financing cash flow in Q1 and said it had paid off all debt in 2021. Current liabilities were $8,151; total liabilities were $8,645, including lease and warranty liabilities. No interest-bearing debt balance was reported for the quarter.
Material changes and management commentary
- Revenue fell 24.2% year over year. Management attributed the decline mainly to Omicron-related closures at bariatric centers from December through February; it reported improved revenue in March.
- Gross margin declined to 50.0% from 70.9%, which management attributed to lower revenue against relatively fixed costs and higher freight costs.
- Sales and marketing expense rose to $4,707 from $1,250, primarily due to expanded direct-to-consumer advertising. General and administrative expense increased to $4,163 from $2,720; research and development increased to $748 from $571.
- Management expected revenue to increase through the rest of 2022, citing direct-to-consumer marketing, web traffic and doctor consultations. This is forward-looking commentary, not quantified guidance.
- Management said available sources were expected to fund working capital and commitments for the next 12 months, while also stating that continued operations depend on executing the business plan and generating revenue. It noted that additional financing may be sought and that there can be no assurance it will be available.
Risks, contingencies, and unusual items
- Liquidity and operating performance remain sensitive to elective-procedure volumes, COVID-19 resurgence, sales execution, and the company’s ability to control spending or raise capital. Q1 operating cash use increased substantially year over year.
- Two unresolved fee disputes were disclosed. Cowen claims a $1.35 million transaction fee, plus interest and legal fees. H.C. Wainwright claims a fee equal to 8% of specified warrant-exercise proceeds, plus interest and legal fees. The company did not accrue amounts and said outcomes were not predictable; it could not estimate Wainwright-related exposure.
- Goodwill was fully impaired in 2021 following a decline in market capitalization. The filing reports no goodwill or indefinite-lived intangible impairment in Q1 2022.
- The company recorded $747 in stock-based compensation in Q1 2022 versus $101 in Q1 2021. It also reported 6,952,335 potentially dilutive warrants excluded from diluted loss per share as anti-dilutive.
- Management reported disclosure controls and procedures were effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for ReShape Lifesciences Inc. (ticker RSLS), not Vyome Holdings, Inc.
- Review the latest cash balance, operating cash burn, financing plans, and whether the company’s stated 12-month liquidity outlook remains valid.
- Track monthly and subsequent-period sales, gross margin, and the results of the direct-to-consumer campaign against management’s expectation of improving 2022 revenue.
- Monitor developments and potential exposure in the Cowen and H.C. Wainwright litigation; neither claim was accrued.
- Assess dilution from warrants, stock awards, and subsequent share-count changes; the filing reported 18,597,522 common shares outstanding at March 31, 2022.